 |
|
|
| |
Phase 1a Safety and Pharmacokinetics (PK) of ABI-H0731,
a Novel Core Protein Allosteric Modifier (CpAM)
|
| |
| |
poster pdf attached
Download the PDF here
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Edward Gane1,2, Christian Schwabe2, KayshapPatel3, Patrick Smith3, Sandy Liaw4, Eric Ruby4, Kelvin Chan4, Leping Li4, Richard Colonno4and Uri Lopatin4
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Trial Unit, Auckland Clinical Studies, Auckland, New Zealand; 3Certara Inc, Princeton, NJ, USA; 4Assembly Biosciences, Inc., San Francisco, CA USA
|
| |
|
|
|
|
|
